Aliases & Classifications for Paraneoplastic Syndromes

MalaCards integrated aliases for Paraneoplastic Syndromes:

Name: Paraneoplastic Syndromes 50 51 69

External Ids:

UMLS 69 C0030472

Summaries for Paraneoplastic Syndromes

NINDS : 50 Paraneoplastic syndromes are a group of rare disorders that are triggered by an abnormal immune system response to a cancerous tumor known as a "neoplasm." Paraneoplastic syndromes are thought to happen when cancer-fighting antibodies or white blood cells (known as T cells) mistakenly attack normal cells in the nervous system. These disorders typically affect middle-aged to older people and are most common in individuals with lung, ovarian, lymphatic, or breast cancer. Neurologic symptoms generally develop over a period of days to weeks and usually occur prior to the tumor being discovered. These symptoms may include difficulty in walking or swallowing, loss of muscle tone, loss of fine motor coordination, slurred speech, memory loss, vision problems, sleep disturbances, dementia, seizures, sensory loss in the limbs, and vertigo or dizziness. Paraneoplastic syndromes include Lambert-Eaton myasthenic syndrome, stiff-person syndrome, encephalomyelitis, myasthenia gravis, cerebellar degeneration, limbic or brainstem encephalitis, neuromyotonia, opsoclonus, and sensory neuropathy.

MalaCards based summary : Paraneoplastic Syndromes is related to neutrophilia, hereditary and osteomalacia, and has symptoms including paraneoplastic opsoclonus ataxia An important gene associated with Paraneoplastic Syndromes is FGF23 (Fibroblast Growth Factor 23). The drugs Mitoxantrone and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and t cells.

Wikipedia : 72 A paraneoplastic syndrome is a syndrome (a set of signs and symptoms) that is the consequence of cancer... more...

Related Diseases for Paraneoplastic Syndromes

Diseases related to Paraneoplastic Syndromes via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 neutrophilia, hereditary 29.9 IL6 PTHLH
2 osteomalacia 29.5 FGF23 PTHLH
3 oncogenic osteomalacia 29.4 FGF23 PTHLH
4 paraneoplastic cerebellar degeneration 11.4
5 autoimmune encephalitis 11.3
6 lambert-eaton myasthenic syndrome 11.2
7 poems syndrome 11.2
8 peritonitis 11.2
9 adenoma 11.2
10 leiomyoma 10.8
11 adrenal adenoma 10.8
12 multicentric reticulohistiocytosis 10.8
13 lung cancer 10.2
14 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
15 small cell cancer of the lung 10.0
16 renal cell carcinoma, nonpapillary 10.0
17 squamous cell carcinoma 9.9
18 lymphoma 9.9
19 hypercalcemia, infantile, 1 9.9
20 metaphyseal chondrodysplasia, jansen type 9.9 FGF23 PTHLH
21 parathyroid gland disease 9.9 FGF23 PTHLH
22 acquired metabolic disease 9.9 IL6 PTHLH
23 mineral metabolism disease 9.9 FGF23 PTHLH
24 thymoma 9.9
25 hepatocellular carcinoma 9.9
26 thymoma, familial 9.9
27 urinary system disease 9.9 FGF23 IL6
28 hypoparathyroidism 9.8 FGF23 PTHLH
29 adenocarcinoma 9.8
30 cerebellar degeneration 9.8
31 leukemia 9.8
32 neuroblastoma 9.8
33 ovarian cancer 9.8
34 acanthosis nigricans 9.7
35 syndrome of inappropriate antidiuretic hormone 9.7
36 ganglioneuroblastoma 9.7
37 laryngitis 9.7
38 oral cancer 9.7
39 adult-onset still's disease 9.7
40 encephalitis 9.7
41 small cell carcinoma 9.7
42 prostatitis 9.7
43 pancreatitis 9.7
44 neuronitis 9.7
45 polymyositis 9.7
46 primary hyperparathyroidism 9.7 FGF23 PTHLH
47 pheochromocytoma 9.7
48 prostate cancer 9.7
49 subacute cerebellar degeneration 9.7
50 melanoma 9.7

Graphical network of the top 20 diseases related to Paraneoplastic Syndromes:



Diseases related to Paraneoplastic Syndromes

Symptoms & Phenotypes for Paraneoplastic Syndromes

UMLS symptoms related to Paraneoplastic Syndromes:


paraneoplastic opsoclonus ataxia

Drugs & Therapeutics for Paraneoplastic Syndromes

Drugs for Paraneoplastic Syndromes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
4
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
5 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
7 Analgesics Phase 4
8 interferons Phase 4,Phase 2
9 Adjuvants, Immunologic Phase 4
10 Topoisomerase Inhibitors Phase 4,Phase 2
11 Antacids Phase 4,Phase 3,Phase 2
12 Anti-Infective Agents Phase 4,Phase 2
13 Interferon-beta Phase 4
14 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
15 Proton pump inhibitors Phase 4,Phase 3,Phase 2
16 Antiviral Agents Phase 4,Phase 2
17
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
18
Zoledronic acid Approved Phase 3,Phase 1,Phase 2 118072-93-8 68740
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
21
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
22
4-Aminopyridine Approved Phase 3,Phase 2 504-24-5 1727
23
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 9579578 4594
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
25 Prednisolone acetate Phase 3
26 glucocorticoids Phase 3,Phase 1
27 Methylprednisolone acetate Phase 3
28 Methylprednisolone Hemisuccinate Phase 3
29 Neuroprotective Agents Phase 3
30 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
31 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
32 Diphosphonates Phase 3,Phase 1,Phase 2
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
34 Ibandronic acid Phase 3
35 Antiemetics Phase 3
36 Prednisolone hemisuccinate Phase 3
37 Prednisolone phosphate Phase 3
38 Anti-Inflammatory Agents Phase 3
39 Protective Agents Phase 3
40 Autonomic Agents Phase 3,Phase 1,Phase 2
41 Bone Density Conservation Agents Phase 3,Phase 1,Phase 2
42 Antirheumatic Agents Phase 3,Phase 2,Phase 1
43 3,4-diaminopyridine Phase 3,Phase 2
44 Immunoglobulins Phase 3,Phase 1,Phase 2
45 Potassium Channel Blockers Phase 3,Phase 2
46 Immunosuppressive Agents Phase 3,Phase 2
47 Antineoplastic Agents, Hormonal Phase 3,Phase 2
48 Antibodies Phase 3,Phase 1,Phase 2
49 Dexamethasone acetate Phase 3 1177-87-3
50 Alkylating Agents Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 74)

# Name Status NCT ID Phase Drugs
1 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
2 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
3 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
4 Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer Unknown status NCT00326820 Phase 3 ibandronate sodium;zoledronic acid;Zolendronic Acid
5 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
6 Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone Completed NCT00003884 Phase 3 zoledronic acid
7 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Completed NCT02970162 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
8 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3 Amifampridine Phosphate;Placebo
9 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
10 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
11 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes Recruiting NCT02562066 Phase 3 amifampridine phosphate;Placebo
12 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
13 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
14 S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone Withdrawn NCT00301886 Phase 3 ibandronate;zoledronate
15 Ephedrine for the Treatment of Congenital Myasthenia Unknown status NCT00541216 Phase 1, Phase 2 Ephedrine
16 Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma Unknown status NCT00202930 Phase 2 anti-CD20 (Rituximab)
17 Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases Completed NCT00060138 Phase 1, Phase 2 zoledronic acid
18 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
19 Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome Completed NCT01511978 Phase 2 Continuous 3,4-DAP;Taper 3,4-DAP to Placebo
20 MC-5A for Chemotherapy Induced Peripheral Neuropathy Completed NCT01261780 Phase 2 Sham device
21 Effectiveness of Rituximab in Pediatric OMS Patients. Completed NCT00244361 Phase 1, Phase 2 rituximab
22 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Completed NCT00896454 Phase 2 denosumab
23 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
24 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
25 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
26 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2 Osilodrostat
27 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2 YF476
28 Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis Not yet recruiting NCT03274375 Phase 2 IA session;Rituximab
29 IVIG Treatment for Refractory Immune-Related Adult Epilepsy Terminated NCT01545518 Phase 2 IVIG
30 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
31 SOM230 Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
32 Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes Completed NCT01203592 Phase 1 Albuterol
33 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
34 Central Pain Study for ABX-1431 Recruiting NCT03138421 Phase 1 ABX-1431 HCl;Placebo
35 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
36 One Week Comparison Study of PTH and PTHrP Infusions Withdrawn NCT01333267 Phase 1 Parathyroid Hormone-related Protein (1-36);parathyroid hormone (1-34);PTH (1-34) and PTHrP (1-36)
37 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
38 Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone Unknown status NCT00458796 zoledronic acid
39 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China Unknown status NCT02559089
40 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area Unknown status NCT02443350
41 Immunotherapy of the Paraneoplastic Syndromes Completed NCT00378326 Tacrolimus
42 Studies of Neurological Paraneoplastic Syndromes Completed NCT00587106
43 One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study Completed NCT00580788 Early Phase 1 PTHrP (1-36)
44 Clinical Trial of a Serious Game for Individuals With SCI/D Completed NCT02341950
45 Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis Completed NCT01865578
46 Pregnancy Outcomes in Congenital Myasthenie Syndrome Completed NCT01474980
47 Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome Completed NCT00806182
48 Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Completed NCT00004832 3,4-diaminopyridine
49 The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress. Completed NCT02253628
50 Nexium Capsules Clinical Experience Investigation Completed NCT01434485

Search NIH Clinical Center for Paraneoplastic Syndromes

Genetic Tests for Paraneoplastic Syndromes

Anatomical Context for Paraneoplastic Syndromes

MalaCards organs/tissues related to Paraneoplastic Syndromes:

38
Lung, Breast, T Cells, Bone, Spinal Cord, Eye, Pancreas

Publications for Paraneoplastic Syndromes

Articles related to Paraneoplastic Syndromes:

(show top 50) (show all 430)
# Title Authors Year
1
Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma. ( 29429069 )
2018
2
Type B lactic acidosis, an uncommon paraneoplastic syndrome. ( 29293400 )
2018
3
Metastatic "Burned Out" Seminoma Causing Neurological Paraneoplastic Syndrome-Not Quite "Burned Out". ( 29441039 )
2018
4
Neuroimmunology of OMS and ANNA-1/anti-Hu paraneoplastic syndromes in a child with neuroblastoma. ( 29318181 )
2018
5
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. ( 28838388 )
2017
6
Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. ( 29191778 )
2017
7
Alopecia areata as a paraneoplastic syndrome of gastric cancer. ( 27990839 )
2017
8
Paraneoplastic syndromes associated with gynecological cancers: A systematic review. ( 28655412 )
2017
9
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. ( 28285700 )
2017
10
Idiopathic Thrombocytopenia Purpura Masking Hodgkin Disease: A Paraneoplastic Syndrome or Simply a Mere Association? ( 29430236 )
2017
11
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature. ( 28285683 )
2017
12
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions. ( 28838389 )
2017
13
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes. ( 28285701 )
2017
14
Much More than Trousseau Syndrome. The Broad Spectrum of the Pancreatic Paraneoplastic Syndromes. ( 28160197 )
2017
15
Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study. ( 28767671 )
2017
16
Endocrine perturbations in POEMS syndrome: Misunderstood features of a rare paraneoplastic syndrome. ( 28495325 )
2017
17
Rheumatic paraneoplastic syndromes - A clinical link between malignancy and autoimmunity. ( 28736272 )
2017
18
A case of acanthosis nigricans as a paraneoplastic syndrome with squamous cell lung cancer. ( 27536145 )
2016
19
Paraneoplastic syndromes revealing ovarian teratoma in young and menopausal women: report of two cases. ( 27795759 )
2016
20
Reply to: "Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients": By BetA1l Vatankulu, Sabire Yilmaz Aksoy, Sait Sager, Metin HalaAs. ( 26669307 )
2016
21
Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes. ( 26711581 )
2016
22
Laryngeal carcinoma presenting as polymyositis: A paraneoplastic syndrome. ( 27011653 )
2016
23
Severe Hyponatremia Presenting as Paraneoplastic Syndrome in a Patient with Small Cell Carcinoma of Gallbladder. ( 27225161 )
2016
24
Papilledema secondary to a superior sagittal sinus thrombosis. Mantle cell lymphoma paraneoplastic syndrome. ( 26596713 )
2016
25
The lung cancer nurse role in the management of paraneoplastic syndromes in lung cancer. ( 27413699 )
2016
26
Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. ( 26914818 )
2016
27
Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. ( 26666237 )
2016
28
Tumour-induced osteomalacia: An emergent paraneoplastic syndrome. ( 26718193 )
2016
29
Autoantibody diversity in paraneoplastic syndromes and related disorders: The need for a more guided screening approach. ( 27287529 )
2016
30
Aggressive cervical neuroblastoma with a rare paraneoplastic syndrome: A therapeutic dilemma. ( 27695211 )
2016
31
Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. ( 27177440 )
2016
32
Paraneoplastic Syndrome in Splenic Marginal Zone Lymphoma: A Rare Phenomenon of Paraplegia as an Atypical Presenting Manifestation. ( 27293921 )
2016
33
Intermittent Fever, Progressive Weight Gain, and Personality Changes in a Five-Year-Old Girl: Unusual Paraneoplastic Syndrome due to Presacral Ganglioneuroma. ( 27413558 )
2016
34
Caution is Needed in Diagnosing IgG4-Related Disease: A Possible Paraneoplastic Syndrome. ( 27863169 )
2016
35
Leukemoid reaction as a paraneoplastic syndrome in hypopharyngeal squamous cell carcinoma with cutaneous metastasis: an exceedingly rare occurrence. ( 26670890 )
2015
36
A rare thymoma case with seven paraneoplastic syndromes. ( 26770603 )
2015
37
Update on neurological paraneoplastic syndromes. ( 26335665 )
2015
38
Membranous glomerulonephritis as a novel paraneoplastic syndrome in a young man with chronic myeloid leukemia. ( 26062944 )
2015
39
Piriform sinus carcinoma with a paraneoplastic syndrome misdiagnosed as adult onset Still's disease: a case report. ( 26770614 )
2015
40
Paraneoplastic Syndrome of Angiomatoid Fibrous Histiocytoma May Be Caused by EWSR1-CREB1 Fusion-induced Excessive Interleukin-6 Production. ( 26165403 )
2015
41
Bicytopenia as a paraneoplastic syndrome for pseudomyxoma peritonei. Hematologic manifestations of a subtle disease. ( 25767403 )
2015
42
Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS syndrome): a paraneoplastic syndrome. ( 26634133 )
2015
43
Resolution of hypercalcemia of malignancy following radical cystectomy in a patient with paraneoplastic syndrome associated with urothelial carcinoma of the bladder. ( 25657552 )
2015
44
A rare case of severe myositis as paraneoplastic syndrome on breast cancer. ( 25890160 )
2015
45
Paraneoplastic Syndromes in Neuro-Ophthalmology. ( 26172160 )
2015
46
Eosinophilic esophagitis as paraneoplastic syndrome in a patient with ganglioneuroblastoma. ( 25985452 )
2015
47
Paraneoplastic Syndromes in Palliative Care: A literature review from a nursing perspective. ( 26514024 )
2015
48
Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. ( 26194717 )
2015
49
Paraneoplastic syndromes: the way to an early diagnosis of lung cancer. ( 26506668 )
2015
50
Different Kinds of Paraneoplastic Syndromes in Childhood Neuroblastoma. ( 26199695 )
2015

Variations for Paraneoplastic Syndromes

Expression for Paraneoplastic Syndromes

Search GEO for disease gene expression data for Paraneoplastic Syndromes.

Pathways for Paraneoplastic Syndromes

GO Terms for Paraneoplastic Syndromes

Biological processes related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 8.8 FGF23 IL6 PTHLH

Molecular functions related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 8.62 FGF23 IL6

Sources for Paraneoplastic Syndromes

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....